Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

245
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
245
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

17.5K
Rescue of recombinant arenaviruses from cloned cDNAs, an approach referred to as reverse genetics, allows researchers to investigate the role of specific viral gene products, as well as the contribution of their different specific domains and residues, to many different aspects of the biology of arenavirus. Likewise, reverse genetics techniques in FDA-approved cell lines (Vero) for vaccine development provides novel possibilities for the generation of effective and safe vaccines to combat human...
17.5K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

40.5K
In this article, we examine the methodology and considerations relevant to the FDA approved depression treatment protocol using the Neuronetics NeuroStar TMS...
40.5K
Isolation and Derivation of Mouse Embryonic Germinal Cells14:01

Isolation and Derivation of Mouse Embryonic Germinal Cells

16.6K
The ability of embryonic germinal cells to differentiate into primordial germinal cells during early development stages is a perfect model to address our hypothesis about cancer and infertility. This protocol shows how to isolate primordial germinal cells from developing gonads in 10.5-11.5 days post coitum mouse...
16.6K
Obedience01:08

Obedience

35.2K
According to obedience research, we may harm others under the forceful pressures of an authority figure (Milgram, 1974). How about if the inappropriate orders were delivered with less force? The increasing interdependence between nurses and physicians compelled Hofling and his colleagues to explore nurses’ reactions to a potentially harmful medical request made by the perceived authority figure, the doctor (Hofling, Brotzman, Dalrymple, Graves, & Pierce, 1966). In this situation,...
35.2K
Ethics in Research01:56

Ethics in Research

25.4K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
25.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tradipitant: First Approval.

Drugs·2026
Same author

Depemokimab: First Approval.

Drugs·2026
Same author

Sibeprenlimab: First Approval.

Drugs·2026
Same author

Rilzabrutinib: First Approval.

Drugs·2025
Same author

Dorocubicel: First Approval.

Molecular diagnosis & therapy·2025
Same author

Paltusotine: First Approval.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
查看所有相关文章

相关实验视频

Updated: Jan 20, 2026

FDA Approved Drugs: Changes to Approved Drugs
01:26

FDA Approved Drugs: Changes to Approved Drugs

Published on: October 3, 2025

245

格尔提尼布:首次获得批准

Arnold Lee1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand. dru@adis.com.

Drugs
|January 18, 2026
PubMed
概括
此摘要是机器生成的。

格丁尼布是一种新的HER2特异性抑制剂,已批准用于治疗HER2突变非小细胞肺癌 (NSCLC). 这一里程碑是在Beamion LUNG-1试验的积极结果之后实现的,为高级NSCLC患者提供了新的治疗选择.

更多相关视频

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.5K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K

相关实验视频

Last Updated: Jan 20, 2026

FDA Approved Drugs: Changes to Approved Drugs
01:26

FDA Approved Drugs: Changes to Approved Drugs

Published on: October 3, 2025

245
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.5K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K

科学领域:

  • 在瘤学瘤学.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 格丁尼布 (HERNEXEOS®) 是一种不可逆转的,HER2 特定的氨酸激酶抑制剂.
  • 它针对具有HER2异常的高级固体瘤,包括HER2突变.
  • 它保留了野生型EGFR的细胞,增强了选择性.

研究的目的:

  • 总结一下 zongertinib 的发展里程碑.
  • 为了突出其在美国首次加速批准NSCLC.

主要方法:

  • 一个Ia/Ib阶段的Beamion LUNG-1试验.
  • 在先前接受治疗的HER2突变NSCLC患者中研究格丁尼布.

主要成果:

  • 从Beamion LUNG-1试验的积极结果导致加速批准.
  • 格丁尼布在HER2突变NSCLC中表现出有效性.

结论:

  • 格丁尼布于2025年8月在美国获得加速批准.
  • 适用于患有不可切除或转移性NSCLC的成年患者,具有特定的HER2突变和先前治疗.